← Back to home

Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)

Clinical trials for Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) trials appear

Sign up with your email to follow new studies for Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug Rina-S shows promise in battling Hard-to-Treat cancers

Disease control Recruiting now

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

Phase 1/2 • Sponsor: Genmab • Aim: Disease control

Last updated Aug 06, 2026 00:00 UTC

Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)

Get alerted when new Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) trials appear

New drug Rina-S shows promise in battling Hard-to-Treat cancers